Additional file 1: Table S1. of PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Creators: name: Ymera Pignochino
name: Capozzi, Federica
name: D’Ambrosio, Lorenzo
name: Dell’Aglio, Carmine
name: Basiricò, Marco
name: Canta, Marta
name: Lorenzato, Annalisa
name: Lutati, Francesca Vignolo
name: Aliberti, Sandra
name: Palesandro, Erica
name: Boccone, Paola
name: Galizia, Danilo
name: Miano, Sara
name: Chiabotto, Giulia
name: Napione, Lucia
name: Gammaitoni, Loretta
name: Sangiolo, Dario
name: Benassi, Maria
name: Pasini, Barbara
name: Chiorino, Giovanna
name: Aglietta, Massimo
name: Grignani, Giovanni
Publisher: name: Figshare
Year: 2017
Subjects: subject: Biochemistry
subject: Space Science
subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Physiology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: FOS: Chemical sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: FOS: Health sciences
subject: Virology

description: Concentrations inhibiting 50% of cell viability (IC50) after 72- h treatment with serial dilutions of trabectedin (2–0.125 nM), olaparib (20–1.25 μM), and veliparib (80–5 μM) as single agents (a) or in constant combination (b, c), and their 95% confidence intervals (95% CI). Population doubling time. Combination index ± estimated standard deviation (est st dev) calculated at IC50 by the Chou-Talalay method for trabectedin and olaparib in combination and trabectedin and veliparib in combination in cell lines of different histotypes: leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), myxoid liposarcoma (LMS), dedifferentiated liposarcoma (DLS), fibrosarcoma (FSA), synovial sarcoma (SS), Ewing’s sarcoma (ES), and osteosarcoma (OS). Supplier and culture conditions are reported for each cell line. Table S2. Direct correlation between combination index (calculated at IC50) and PARP1 protein intensity expressed as Pearson score (r Pearson). IC50 and 95% confidence intervals (95% CI) were calculated after 72-h treatment with serial dilutions of trabectedin (2–0.125 nM), olaparib (20–1.25μM), and their constant combination. Cell line characteristics, population doubling time, purchasers and culture conditions were included. Table S3. Gene expression (ΔCT) of DNA-damage response and repair key components and drug synergism expressed by combination index (CI). The correlation between each gene expression and the CI was evaluated by Pearson score (r); t distribution and their relative P value were shown. Yellow cells highlight significant direct correlation. Table S4. PARP1 gene (chromosome 1 q42.12d) copy number obtained by FISH. Table S5. PARP1, BRCA1, RAD51 gene copy number obtained by real- time PCR on genomic DNA. The gene copy number of PARP1, RAD51, and BRCA1 did not correlate with the Combination index (CI) as shown by Pearson score. Table S6. Genomic status of selected genes analyzed by MLPA and DHPLC /Sequencing. Red cells indicate increased copy number, while blue cells indicate reduced copy number as obtained by DHPLC analysis. Table S7. Immunohistochemistry score of intensity for PARP1, BRCA1, and RAD51 protein expression in formalin-fixed paraffin-embedded sarcoma samples. Table S8. 2 × 2 contingency tables of immunohistochemistry (IHC) expression of PARP1, BRCA1, and RAD51 in patient-derived soft tissue and bone sarcoma specimens (a, b, c) and related concordance rates (d). (DOCX 2086 kb)